Incidence and long-term prognosis of papillary compared to clear cell renal cell carcinoma – A multicentre study

Steffens, Sandra; Janssen, Martin; Roos, Frederik C.; Becker, Frank; Schumacher, Simon; Seidel, Christoph; Wegener, Gerd; Thüroff, Joachim W.; Hofmann, Rainer; Stöckle, Michael; Siemer, Stefan; Schrader, Mark; Hartmann, Arndt; Kuczyk, Markus A.; Junker, Kerstin; Schrader, Andres Jan

doi:10.1016/j.ejca.2012.05.002

Cited by 116 publications

(97 citation statements)

References 25 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…In the metastatic setting, pRCC prognosis is worse than ccRCC prognosis, especially in type II subpopulation (6,26,27). Currently, there is no standard of care for systemic treatment of metastatic pRCC.…”

Section: Discussionmentioning

confidence: 99%

MET Is a Potential Target across All Papillary Renal Cell Carcinomas: Result from a Large Molecular Study of pRCC with CGH Array and Matching Gene Expression Array

Albigès

Guégan

Formal

et al. 2014

Clinical Cancer Research

141

View full text Add to dashboard Cite

Purpose: Papillary renal cell carcinomas (pRCC) are the most common nonclear cell RCC subtype. Germline mutations of the MET oncogene at 7q31 have been detected in patients with hereditary type I pRCC and in 13% of sporadic type I pRCC. Recent report of MET inhibition strengthened the role of c-Met inhibition across pRCC.Experimental Design: We collected 220 frozen samples of sporadic pRCC through the French RCC Network and quality controlled for percentage of malignant cells >70%. Gene expression was assessed on 98 pRCC using human whole-genome Agilent 8 Â 60K arrays. Copy number alterations were analyzed using Agilent Human 2 Â 400K and 4Â 180K array for type II pRCC and comparative genomic microarray analysis method for type I pRCC. MET gene sequencing was performed on type I pRCC.Results: MET expression level was high across all pRCC. We identified copy number alterations (gain) in 46% of type II pRCC and in 81% of type I pRCC. Correlation between DNA copy number alterations and mRNA expression level was highly significant. Eleven somatic mutations of MET gene were identified amongst 51 type I pRCC (21.6%), including 4 new mutations. We validated LRRK2 cokinase as highly correlated to MET expression.

show abstract

Section: Discussionmentioning

confidence: 99%

MET Is a Potential Target across All Papillary Renal Cell Carcinomas: Result from a Large Molecular Study of pRCC with CGH Array and Matching Gene Expression Array

Albigès

Guégan

Formal

et al. 2014

Clinical Cancer Research

141

View full text Add to dashboard Cite

show abstract

“…Papillary renal cell carcinomas are generally smaller and have fewer metastases at diagnosis compared with clear cell renal cell carcinomas with similar or favorable cancer specific survivals [17,18]. Papillary renal cell carcinomas are further differentiated into type 1 and type 2 with the latter having significant lymphovascular invasion and poorer prognosis [18].…”

Section: Discussionmentioning

confidence: 99%

HMGB1 and HMGB2 Expression Patterns in Human Papillary Renal Cancers

Takeuchi¹,

Sakazume²,

Tonooka³

et al. 2013

OJU

View full text Add to dashboard Cite

High mobility group box (HMGB) proteins are nuclear nonhistone chromosomal proteins that bend DNA, bind preferentially to distorted DNA structures, and promote the assembly of site-specific DNA binding proteins. Recent reports indicate that HMGB1 has a dual function, a cytokine in addition to a nuclear protein. The increased expression of HMGB1 has been reported for several different tumors. Here, we assessed HMGB1 and HMGB2 expressions in two cases of papillary renal cell carcinoma. One case with pT1a, Grade 2 showed HMGB1 expression in the nucleus and cytosol and HMGB2 expression in the nucleus, but not in the cytosol. In the other case, there were three renal tumors, one of which was clear cell renal cell carcinoma with pT1a, Grade 3 and two were papillary renal cell carcinomas, Grade 2 (5 mm and 2 mm in the diameter). Both HMGB1 and HMGB2 were expressed in the nucleus and cytosol of papillary carcinoma. In the clear cell carcinoma of this case, HMGB1 expression was stained both in the nucleus and cytosol, while HMGB2 was observed in the nucleus, but not in the cytosol. More samples need to be further investigated in order to draw conclusions concerning HMGB expressions in papillary renal cell carcinomas.

show abstract

“…Следовательно, выводы этого исследования распространяются на всю популяцию больных ПКР, что находит отражение в реальной практике. Так, в 2 крупных ретроспективных анализах (n = 2675 [12] и n = 4824 [9]) было показано, что резекция почки вы-полняется достоверно чаще, чем РНЭ (p < 0,001) у па-циентов с нПКР и стадией ≤ T3a. В первом исследова-нии отличий по ОВ между гистологическими типами ПКР не наблюдалось (ОР 0,90; p = 0,25) [12].…”

Section: хирургическое лечение нпкрunclassified

“…В первом исследова-нии отличий по ОВ между гистологическими типами ПКР не наблюдалось (ОР 0,90; p = 0,25) [12]. В другом исследовании, как было описано выше, авторы выяви-ли преимущества в выживаемости у больных нПКР [9]. У пациентов с локализованным кистозным ПКР (T1-2) РНЭ выполняли чаще -в 60 % случаев, а резекцию почки -в 40 % (p < 0,001).…”

Section: хирургическое лечение нпкрunclassified

“…Например, в нескольких ретро-спективных исследованиях авторы продемонстрировали отсутствие влияния метастазов в региональные лимфа-тические узлы (N0 по сравнению с N1-N2) на опухоле-воспецифическую выживаемость (ОСВ) у пациентов с различными подтипами папиллярного ПКР [5], суще-ственные различия в ОСВ пациентов с кистозным и светлоклеточным ПКР со стадией pT1b / T2 [6], досто-верное повышение частоты синхронного метастазиро-вания у больных светлоклеточным ПКР по сравнению с папиллярным (p = 0,002) и хромофобным (p = 0,02) ПКР независимо от размера первичной опухоли [7] или наличие только 1 независимого фактора, влияюще-го на общую выживаемость (ОВ) больных медуллярным ПКР, -метастазов на момент постановки диагноза [8]. В многоцентровом ретроспективном исследовании, объ-единившем 4941 пациента со светлоклеточным и папил-лярным ПКР, было отмечено значимое влияние гисто-логического подтипа рака почки независимо от других факторов многофакторного анализа (пол, возраст, стадия T, степень дифференцировки) на ОСВ у пациентов со стадией pT1-4, N / M0 [9]. Пятилетняя ОСВ состави-ла 94,5 % в группе пациентов с папиллярным ПКР и 86,9 % в группе светлоклеточного ПКР (отношение рисков (ОР) 0,45; p < 0,001).…”

unclassified

See 1 more Smart Citation